Rapamycin News and Research

RSS

Rapamycin is a drug used to prevent the rejection of organ and bone marrow transplants by the body. Rapamycin is an antibiotic that blocks a protein involved in cell division and inhibits the growth and function of certain T cells of the immune system involved in the body's rejection of foreign tissues and organs. It is a type of immunosuppressant and a type of serine/threonine kinase inhibitor. Rapamycin is now called sirolimus.

Metastatic site impacts survival in targeted RCC treatment

Bone and liver metastases may have the heaviest impact on the survival of patients receiving targeted therapy for metastatic renal cell carcinoma, suggest data from the International Metastatic Renal Cell Carcinoma Database Consortium.

8 Oct 2013

Specialized cells play major role in inflammation that underlies Crohn's disease in small intestine

Scientists have discovered that Crohn's disease, the inflammatory bowel disorder, can originate from specialised intestinal cell type called Paneth cells. As such, they propose that small intestinal Crohn's disease might be a specific disorder of this cell type, providing a possible new target for treatments.

3 Oct 2013

First Phase II study: Everolimus drug slows spread of advanced papillary kidney cancer

The first Phase II study to investigate the use of the anti-cancer drug, everolimus, for the initial treatment of advanced papillary kidney cancer has shown that it is successful in slowing or preventing the spread of the disease, according to research to be presented today (Sunday) at the 2013 European Cancer Congress.

29 Sep 2013

Metastatic site impacts survival in targeted RCC treatment

24 Sep 2013

Four new pre-clinical drug development projects at NIH develop treatment for rare disease

Four new pre-clinical drug development projects at the National Institutes of Health will target a form of blindness and diseases characterized by cardiac problems. The projects were selected for their potential to treat specific rare diseases and to help scientists uncover new information that can be shared with other researchers.

13 Sep 2013

Research suggests blocking DNA repair complex helps fight therapy-resistant leukemia

New research posted online by the Nature journal Leukemia suggests blocking part of a DNA repair complex that helps some types of leukemia resist treatment can increase the effectiveness of chemotherapy and enhance survival.

9 Aug 2013

Researchers now have more complete picture of mTORC1 pathway that can lead to cancer, diabetes

Deciphering the body's complex molecular pathways that lead to disease when they malfunction is highly challenging. Researchers at Sanford-Burnham Medical Research Institute now have a more complete picture of one particular pathway that can lead to cancer and diabetes. In the study published by Molecular Cell, the scientists uncovered how a protein called p62 has a cascade affect in regulating cell growth in response to the presence of nutrients such as amino acids and glucose. Disrupting this chain may offer a new approach to treating disease.

2 Aug 2013

Rapamycin extends mice lifespan but has limited effects on aging

The body's repair mechanisms begin to fail with increasing age. As a result, signs of wear and tear appear and the risk for many diseases, including Alzheimer's disease, diabetes, cardiovascular disorders and cancer, increases.

26 Jul 2013

Novel way to fine-tune activity of cells' protein-disposing machinery with cancer-fighting effects

Molecular biologists in the School of Medicine at The University of Texas Health Science Center San Antonio have found a novel way to fine-tune the activity of cells' protein-disposing machinery, with potentially cancer-fighting effects.

18 Jul 2013

Autism Speaks funds high priority research for treatment of ASD

Autism Speaks, the world's leading autism science and advocacy organization, today announced awards totaling $685,968 funding new research in areas of high priority that will advance understanding and treatment of autism spectrum disorders (ASD).

27 Jun 2013

New study points to potential strategy for erasing memory of addiction

A new study by researchers at the Ernest Gallo Clinic and Research Center at UC San Francisco offers encouraging findings that researchers hope may one day lead to a treatment option for people who suffer from alcohol abuse disorders and other addictions.

25 Jun 2013

Researchers discover reason behind failed anti-cancer therapy

Researchers at the Hebrew University of Jerusalem and in California have achieved a breakthrough in understanding how and why a promising anti-cancer therapy has failed to achieve hoped-for success in killing tumor cells.

24 Jun 2013

Combination therapy with myxoma virus and rapamycin can kill glioblastoma multiforme

A combination of the myxoma virus and the immune suppressant rapamycin can kill glioblastoma multiforme, the most common and deadliest malignant brain tumor, according to Moffitt Cancer Center research.

21 Jun 2013

Too much sugar can lead to heart failure, shows study

Too much sugar can set people down a pathway to heart failure, according to a study led by researchers at The University of Texas Health Science Center at Houston (UTHealth).

15 Jun 2013

Rapamycin improves cardiac function in mice suffering from age-related heart disease

Elderly mice suffering from age-related heart disease saw a significant improvement in cardiac function after being treated with the FDA-approved drug rapamycin for just three months.

11 Jun 2013

Inflection Biosciences signs license agreement with CNIO to develop kinase inhibitors for cancer treatment

Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that it has entered into a license agreement with the Spanish National Cancer Research Centre (CNIO) for the exclusive, worldwide rights to develop and commercialise several novel kinase inhibitors for the treatment of cancer.

6 Jun 2013

Researchers discover how drug prevents cancer progression

In collaboration with Daniel Zenklusen, also a University of Montreal biochemistry professor and lead author and doctoral candidate Vincent Messier, discovered that when cells are starved for nutrients TOR sends a signal to shut down production of a chemical message in the form of RNA to synthesize B cyclin ", Dr. Michnick explained.

24 May 2013

Everolimus reverses trastuzumab resistance in early HER-2 positive breast cancer

A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle.

3 May 2013

Targeted therapy prevents rare neurodevelopmental disorder seizures

Rapamycin treatment reduces seizure frequency and improves receptive language in patients with polyhydramnios, megalencephaly, and symptomatic epilepsy syndrome, or Pretzel syndrome, a study finds.

29 Apr 2013

Sirolimus effective in treating children with Pretzel syndrome, new study reports

With a better understanding of underlying mechanisms that cause a rare neurodevelopmental disorder in the Old Order Mennonite population, referred to as Pretzel syndrome, a new study reports that five children were successfully treated with a drug that modifies the disease process, minimizing seizures and improving receptive language.

25 Apr 2013

Rapamycin News and Research

Metastatic site impacts survival in targeted RCC treatment

Specialized cells play major role in inflammation that underlies Crohn's disease in small intestine

First Phase II study: Everolimus drug slows spread of advanced papillary kidney cancer

Metastatic site impacts survival in targeted RCC treatment

Four new pre-clinical drug development projects at NIH develop treatment for rare disease

Research suggests blocking DNA repair complex helps fight therapy-resistant leukemia

Researchers now have more complete picture of mTORC1 pathway that can lead to cancer, diabetes

Rapamycin extends mice lifespan but has limited effects on aging

Novel way to fine-tune activity of cells' protein-disposing machinery with cancer-fighting effects

Autism Speaks funds high priority research for treatment of ASD

New study points to potential strategy for erasing memory of addiction

Researchers discover reason behind failed anti-cancer therapy

Combination therapy with myxoma virus and rapamycin can kill glioblastoma multiforme

Too much sugar can lead to heart failure, shows study

Rapamycin improves cardiac function in mice suffering from age-related heart disease

Inflection Biosciences signs license agreement with CNIO to develop kinase inhibitors for cancer treatment

Researchers discover how drug prevents cancer progression

Everolimus reverses trastuzumab resistance in early HER-2 positive breast cancer

Targeted therapy prevents rare neurodevelopmental disorder seizures

Sirolimus effective in treating children with Pretzel syndrome, new study reports

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News